• HUTCHMED will co-host an investor and analyst webcast with Citigroup on November 5, 2026.
• The event starts at 4:30 p.m. HKT / 8:30 a.m. GMT / 3:30 a.m. EST.
• Discussions will cover Phase III savolitinib data in MET-driven non-small cell lung cancer, including development progress and the global regulatory outlook.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610262000PRIMZONEFULLFEED9853281) on October 27, 2026, and is solely responsible for the information contained therein.